denny
12-01-2011, 05:18 AM
Another article on Replicel yesterday. Mentioning their successful progress in clinical trials as well as it seems they are converting their stock to make the company more appealing to financiers... http://editorial.equities.com/spotlight-companies/replicel-converts-class-c-shares-to-common-stock/